imp288

mAbexperimentalImaging agent

Clinical trial activity

5 trials · 8 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2009 (NCT00860860)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Multi-specific
No
Imaging
111-indium

Oral

No

Parenteral

No

Topical

No

Also known as

  • dota-d-tyr-d-lys(hsg)-d-glu-d-lys(hsg)-nh2
  • dota-tyr-lys(hsg)-glu-lys(hsg)-nh2
  • dota-tyrosyl-lysyl(histaminyl-succinyl-glycyl)-glutamyl-lysyl(histaminyl-succinyl-glycyl)amide
  • imp288
  • imp 288
  • imp-288
  • imp-288

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT02587247Phase 2Mar 1, 2016University of Nantes
NCT01730612Phase 1/Phase 2 (Phase 2)Dec 1, 2012Immunomedics, Institut National de la Santé Et de la Recherche Médicale, France, University of Nantes
NCT01221675Phase 1/Phase 2 (Phase 2)Jun 1, 2011Institut de Cancerologie de l'Ouest Paul Papin
NCT01273402Phase 1Feb 1, 2011Garden State Cancer Center, Immunomedics, National Cancer Institute (NCI)
NCT00860860Phase 1Jul 1, 2009Radboud University, Richmond University
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (8)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
ImmunomedicsFor profit2122011
University of NantesAcademic/Hospital2212012
Garden State Cancer CenterAcademic/Hospital1012011
Institut de Cancerologie de l'Ouest Paul PapinAcademic/Hospital1112011
Institut National de la Santé Et de la Recherche Médicale, FranceAcademic/Hospital1012012
National Cancer Institute (NCI)Government1012011
Radboud UniversityAcademic/Hospital1112009
Richmond UniversityAcademic/Hospital1012009
8 organizations
Page 1 / 1